Pharmaceutical company Dara BioSciences has launched its Oravig tablet to treat oral thrush for the U.S. oncology and primary care markets.
Oravig is an orally dissolving mucoadhesive buccal tablet containing miconazole that is approved by the U.S. Food and Drug Administration to treat oropharyngeal candidiasis, according to the company.
"Oravig gives healthcare providers a much-needed option, as an excellent localized therapy solution which adheres to the oral mucosa and provides sustained, local release of miconazole over a period of several hours with just one daily application," stated Dr. David Drutz, chief medical officer of Dara, in a press release.
Dara was granted exclusive U.S. rights to Oravig in March 2015 under a commercialization agreement with Onxeo, a Paris-based biopharmaceutical company that specializes in the development of orphan oncology drugs.
Oravig will be supported by the company's No Coupon, No Co-pay, No Hassles program, that provides a reduction or elimination of prescription co-pays by offsetting out-of-pocket expenses for qualified patients. The program is applied automatically to qualified prescriptions at more than 43,000 U.S. pharmacies. The company also offers a patient assistance program for those patients who are either under- or uninsured.
